Literature DB >> 20197138

Rotavirus enterotoxin NSP4 has mucosal adjuvant properties.

Owen V Kavanagh1, Nadim J Ajami, Elly Cheng, Max Ciarlet, Roberto A Guerrero, Carl Q-Y Zeng, Sue E Crawford, Mary K Estes.   

Abstract

Rotavirus nonstructural protein 4 (NSP4) is a protein with pleiotropic properties. It functions in rotavirus morphogenesis, pathogenesis, and is the first described viral enterotoxin. Since many bacterial toxins function as potent mucosal adjuvants, we evaluated whether baculovirus-expressed recombinant simian rotavirus SA11 NSP4 possesses adjuvant activity by co-administering NSP4 with keyhole limpet hemocyanin (KLH), tetanus toxoid (TT) or ovalbumin (OVA) as model antigens in mice. Following intranasal immunization, NSP4 significantly enhanced both systemic and mucosal immune responses to model immunogens, as compared to the control group, in an antigen-specific manner. Both full-length and a cleavage product of SA11 NSP4 had adjuvant activity, localizing this activity to the C-terminus of the protein. NSP4 forms from virulent and avirulent porcine rotavirus OSU strain, and SA11 NSP4 localized within a 2/6-virus-like particle (VLP) also exhibited adjuvant effects. These studies suggest that the rotavirus enterotoxin NSP4 can function as an adjuvant to enhance immune responses for a co-administered antigen. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20197138      PMCID: PMC3663485          DOI: 10.1016/j.vaccine.2010.02.063

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  28 in total

1.  A functional NSP4 enterotoxin peptide secreted from rotavirus-infected cells.

Authors:  M Zhang; C Q Zeng; A P Morris; M K Estes
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues.

Authors:  F W van Ginkel; R J Jackson; Y Yuki; J R McGhee
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

3.  Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice.

Authors:  Andrea Bertolotti-Ciarlet; Max Ciarlet; Sue E Crawford; Margaret E Conner; Mary K Estes
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

4.  Uterine granular lymphocytes are activated natural killer cells expressing VLA-1.

Authors:  J Dietl; P Ruck; K Marzusch; H P Horny; E Kaiserling; R Handgretinger
Journal:  Immunol Today       Date:  1992-06

Review 5.  Virus-like particle vaccines and adjuvants: the HPV paradigm.

Authors:  Franco Maria Buonaguro; Maria Lina Tornesello; Luigi Buonaguro
Journal:  Expert Rev Vaccines       Date:  2009-10       Impact factor: 5.217

6.  Functional analysis of alpha 1 beta 1 integrin in human natural killer cells.

Authors:  J J Pérez-Villar; I Melero; A Gismondi; A Santoni; M López-Botet
Journal:  Eur J Immunol       Date:  1996-09       Impact factor: 5.532

7.  Mutations in rotavirus nonstructural glycoprotein NSP4 are associated with altered virus virulence.

Authors:  M Zhang; C Q Zeng; Y Dong; J M Ball; L J Saif; A P Morris; M K Estes
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 8.  A rational basis for mucosal vaccination against HIV infection.

Authors:  T Lehner; L Bergmeier; Y Wang; L Tao; E Mitchell
Journal:  Immunol Rev       Date:  1999-08       Impact factor: 12.988

9.  A second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking.

Authors:  Yukari Hagiwara; Yuki I Kawamura; Kosuke Kataoka; Bibi Rahima; Raymond J Jackson; Katsuhiro Komase; Taeko Dohi; Prosper N Boyaka; Yoshifumi Takeda; Hiroshi Kiyono; Jerry R McGhee; Kohtaro Fujihashi
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

10.  Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice.

Authors:  J M Ball; M E Hardy; R L Atmar; M E Conner; M K Estes
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

View more
  6 in total

1.  HSV-1 amplicon vectors launch the production of heterologous rotavirus-like particles and induce rotavirus-specific immune responses in mice.

Authors:  Andrea S Laimbacher; Laura E Esteban; Alejandro A Castello; Juan C Abdusetir Cerfoglio; Marcelo H Argüelles; Graciela Glikmann; Alejandra D'Antuono; Nora Mattion; Mabel Berois; Juan Arbiza; Monika Hilbe; Elisabeth M Schraner; Michael Seyffert; Christiane Dresch; Alberto L Epstein; Mathias Ackermann; Cornel Fraefel
Journal:  Mol Ther       Date:  2012-06-19       Impact factor: 11.454

2.  Rotavirus NSP4 Triggers Secretion of Proinflammatory Cytokines from Macrophages via Toll-Like Receptor 2.

Authors:  Yi Ge; Ashley Mansell; James E Ussher; Anna E S Brooks; Kristy Manning; Carol J H Wang; John A Taylor
Journal:  J Virol       Date:  2013-08-07       Impact factor: 5.103

3.  Effects of rotavirus NSP4 protein on the immune response and protection of the SR69A-VP8* nanoparticle rotavirus vaccine.

Authors:  Cunbao Liu; Pengwei Huang; Dandan Zhao; Ming Xia; Weiming Zhong; Xi Jiang; Ming Tan
Journal:  Vaccine       Date:  2020-12-11       Impact factor: 4.169

4.  Designing, Construction and Expression of a Recombinant Fusion Protein Comprising the Hepatitis E Virus ORF2 and Rotavirus NSP4 in the Baculovirus Expression System.

Authors:  Manoochehr Makvandi; Ali Teimoori; Niloofar Neisi; Alireza Samarbafzadeh
Journal:  Jundishapur J Microbiol       Date:  2016-10-08       Impact factor: 0.747

5.  Analysis of NSP4 Gene and Its Association with Genotyping of Rotavirus Group A in Stool Samples

Authors:  Ali Teimoori; Mehrab Nejati; Saeedeh Ebrahimi; Manoochehr Makvandi; Milad Zandi; Azarakhsh Azaran
Journal:  Iran Biomed J       Date:  2017-07-11

6.  Oral Administration of a Seed-based Bivalent Rotavirus Vaccine Containing VP6 and NSP4 Induces Specific Immune Responses in Mice.

Authors:  Hao Feng; Xin Li; Weibin Song; Mei Duan; Hong Chen; Tao Wang; Jiangli Dong
Journal:  Front Plant Sci       Date:  2017-05-31       Impact factor: 5.753

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.